August 27, 2017 / 11:43 PM / 3 months ago

BRIEF-CSL says CSL Behring acquires Calimmune

Aug 28 (Reuters) - Csl Ltd

* CSL Behring acquires us biotech company calimmune-csl.ax

* Deal for an upfront payment of $91 million.

* Additionally, CSL Behring will acquire two proprietary platform technologies, Select and Cytegrity

* Additional research and development expenditure is expected to be contained within CSL’s previously announced guidance

* CSL Behring will have operational control of Calimmune following closing of transaction

* deal includes potential for milestone payments of up to $325 million over a period anticipated to be around eight years or more following closing Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below